AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8564394 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar groups
Number of subjects: 0
Study 8564394 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar groups
Number of subjects: 0
Study 2515634 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone)
Number of subjects: 52
Study 2515634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 320955 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 31
Study 320955 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific therapy
Number of subjects: 31
Study 320955 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 31
Study 31034297 — intervention group
Group type: EXPERIMENTAL
Intervention: Judo training (1 hr session, biweekly for 4 months)
Number of subjects: 30
Study 31034297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 28497218 — intervention group
Group type: EXPERIMENTAL
Intervention: Integra Flowable Wound Matrix
Number of subjects: 60
Study 28497218 — intervention group
Group type: COMPARATOR
Intervention: Wet dressing
Number of subjects: 60
Study 25349107 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen plus antioxidant cocktail (grape seed extract, vitamin E, ubiquinone, vitamin C)
Number of subjects: 30
Study 25349107 — intervention group
Group type: COMPARATOR
Intervention: SPF 30 sunscreen alone
Number of subjects: 30
Study 24708480 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg infusion intra-operatively, 10 mg orally for the first three nights post-surgery)
Number of subjects: 50
Study 24708480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24708480 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 50
Study 22285168 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day
Number of subjects: 174
Study 22285168 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (cisplatin 75 mg/m2 plus docetaxel 75 mg/m2 or gemcitabine 1250 mg/m2)
Number of subjects: 174
Study 22285168 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 174
Study 22285168 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 174
Study 20530392 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated group (tailored, intensive assistance and services from TransforMED)
Number of subjects: 36
Study 20530392 — intervention group
Group type: COMPARATOR
Intervention: Self-directed group (very limited assistance)
Number of subjects: 36
Study 17639157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of multimixture added to school meals
Number of subjects: 24
Study 17639157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no multimixture)
Number of subjects: 24
Study 15778243 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment for 6 weeks
Number of subjects: 25
Study 15778243 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment for 24 weeks
Number of subjects: 25
Study 15778243 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 15778243 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 25
Study 11870097 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicine treatments (specific interventions not detailed)
Number of subjects: 0
Study 11870097 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials of alternative medicine
Number of subjects: 0
Study 11870097 — intervention group
Group type: EXPERIMENTAL
Intervention: Impeccable papers proving absurd claims
Number of subjects: 0
Study 9704959 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative enteral feeding (feeding jejunostomy, low-residue milk-based diet)
Number of subjects: 43
Study 9704959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immediate postoperative enteral feeding)
Number of subjects: 43
Study 9704959 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 9704959 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 43
Study 9704959 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 43
Study 8726297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin, 120 mg/day
Number of subjects: 49
Study 8726297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 1872019 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast recombinant pre‐S2 + S vaccine (12, 24 or 48 micrograms)
Number of subjects: 104
Study 1872019 — intervention group
Group type: COMPARATOR
Intervention: Recombivax HBR (10 micrograms)
Number of subjects: 104
Study 1872019 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast recombinant pre‐S2 + S vaccine
Number of subjects: 104
Study 1872019 — intervention group
Group type: COMPARATOR
Intervention: Recombivax HBR
Number of subjects: 104
Study 7050878 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge Teflon catheter
Number of subjects: 34
Study 7050878 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge steel needle
Number of subjects: 34
Study 31349110 — intervention group
Group type: EXPERIMENTAL
Intervention: BALANCE Program
Number of subjects: 2534
Study 31349110 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition advice (control group)
Number of subjects: 2534
Study 29229219 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 50
Study 29229219 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional fluoroscopic technique)
Number of subjects: 50
Study 26950692 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT) for 2 years of weekly sessions
Number of subjects: 70
Study 26950692 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT) for 5 months
Number of subjects: 70
Study 26950692 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 70
Study 26950692 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 70
Study 24342121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (RA)
Number of subjects: 80
Study 24342121 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 80
Study 22458939 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 60 mg bid
Number of subjects: 838
Study 22458939 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 5 mg bid
Number of subjects: 838
Study 22458939 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 20 mg bid
Number of subjects: 838
Study 22458939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 19543000 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 90
Study 19543000 — intervention group
Group type: EXPERIMENTAL
Intervention: granisetron 1 mg
Number of subjects: 90
Study 19543000 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 90
Study 17380590 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg, 40 mg, and 60 mg single doses
Number of subjects: 88
Study 17380590 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 20 mg and 40 mg twice-daily for 5 days
Number of subjects: 88
Study 17380590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 15450676 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (50 mg)
Number of subjects: 36
Study 15450676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.12 mg bolus followed by 0.5 mg/kg over 60 min)
Number of subjects: 36
Study 15450676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 36
Study 15450676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 36
Study 11408234 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg intravenous
Number of subjects: 18
Study 11408234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9818104 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT2 antagonist (sarpogrelate hydrochloride, 300 mg a day po)
Number of subjects: 33
Study 9818104 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated stellate ganglion blocks (SGBs) with mepivacaine
Number of subjects: 33
Study 9818104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (5-HT2 antagonist with SGBs)
Number of subjects: 33
Study 9006217 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback counselling (1 or 2 sessions of 15-30 minutes each, including supervised testing and error correction)
Number of subjects: 71
Study 9006217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no individualized feedback counselling)
Number of subjects: 71
Study 2506490 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lipidic emulsion based on safflower oil and soya (Liposyn II)
Number of subjects: 20
Study 2506490 — intervention group
Group type: COMPARATOR
Intervention: 10% Intralipid
Number of subjects: 20
Study 772172 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine treatment (n=23)
Number of subjects: 45
Study 772172 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=22)
Number of subjects: 45
Study 31947853 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (50 g)
Number of subjects: 80
Study 31947853 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (50 g)
Number of subjects: 80
Study 31947853 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 80
Study 31947853 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 80
Study 30844048 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 1070
Study 30844048 — intervention group
Group type: COMPARATOR
Intervention: Non-febuxostat (conventional therapy with lifestyle modification)
Number of subjects: 1070
Study 28709022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills-based intervention
Number of subjects: 93
Study 28709022 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training control condition
Number of subjects: 93
Study 25883166 — intervention group
Group type: EXPERIMENTAL
Intervention: InsuPad device
Number of subjects: 14
Study 25883166 — intervention group
Group type: COMPARATOR
Intervention: No InsuPad device (control)
Number of subjects: 14
Study 22732180 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (9 g daily for 6 months)
Number of subjects: 88
Study 22732180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 88
Study 21167859 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS02 vaccine (two doses given one month apart)
Number of subjects: 432
Study 21167859 — intervention group
Group type: COMPARATOR
Intervention: Licensed conventional recombinant hepatitis B vaccine (HBVAXPRO™; two doses)
Number of subjects: 432
Study 21167859 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS02 vaccine (single booster dose)
Number of subjects: 432
Study 21167859 — intervention group
Group type: COMPARATOR
Intervention: Licensed conventional recombinant hepatitis B vaccine (single booster dose)
Number of subjects: 432
Study 18042311 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate 150 mg
Number of subjects: 0
Study 18042311 — intervention group
Group type: COMPARATOR
Intervention: Weekly alendronate 70 mg
Number of subjects: 0
Study 16879331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed handpiece + 37% phosphoric acid
Number of subjects: 30
Study 16879331 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350 mJ, 4 Hz and 112 J/cm(2)) + 37% phosphoric acid
Number of subjects: 30
Study 16879331 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350 mJ, 4 Hz and 112 J/cm(2)) + Er:YAG laser (80 mJ, 4 Hz, and 25 mJ/cm(2))
Number of subjects: 30
Study 16879331 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser preparation
Number of subjects: 30
Study 14708420 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 24
Study 14708420 — intervention group
Group type: COMPARATOR
Intervention: Oxybutinin (0.4 mg/kg)
Number of subjects: 24
Study 11179910 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin alone (arm A)
Number of subjects: 21
Study 11179910 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin with formestane (arm B)
Number of subjects: 21
Study 9310809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 27
Study 9310809 — intervention group
Group type: COMPARATOR
Intervention: Non-clonidine treatment
Number of subjects: 27
Study 9310809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine treatment
Number of subjects: 27
Study 8311748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of posterior leaflet and chordae tendineae (group 1)
Number of subjects: 21
Study 8311748 — intervention group
Group type: COMPARATOR
Intervention: Conventional mitral valve replacement (group 2)
Number of subjects: 21
Study 3753293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium antagonist (nifedipine)
Number of subjects: 50
Study 3753293 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naftidrofuryl with vitamin A, vitamin E, and zinc
Number of subjects: 50
Study 30256884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 1
Study 26588809 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g transdermal testosterone gel (TT) (N = 16)
Number of subjects: 43
Study 26588809 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (AI) 1 mg (N = 14)
Number of subjects: 43
Study 26588809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 13)
Number of subjects: 43
Study 24695894 — intervention group
Group type: EXPERIMENTAL
Intervention: In-store marketing intervention for 6 months promoting healthier products through placement, signage, and product availability strategies.
Number of subjects: 8
Study 24695894 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention (assessment-only).
Number of subjects: 8
Study 23171568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaboration program
Number of subjects: 0
Study 23171568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19851858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive neoadjuvant therapy
Number of subjects: 274
Study 19851858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis assays
Number of subjects: 274
Study 17941031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT) screening for lung cancer
Number of subjects: 0
Study 17941031 — intervention group
Group type: COMPARATOR
Intervention: Simulated control group
Number of subjects: 0
Study 17941031 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 0
Study 16188549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 0
Study 16188549 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy using BMPs
Number of subjects: 0
Study 11861035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17 beta-estradiol continuously plus sequential progestagen over 1 year
Number of subjects: 51
Study 11861035 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of HRT after 12 months
Number of subjects: 51
Study 10439739 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexital-desflurane
Number of subjects: 120
Study 10439739 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexital-sevoflurane
Number of subjects: 120
Study 10439739 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-desflurane
Number of subjects: 120
Study 10439739 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-sevoflurane
Number of subjects: 120
Study 9732842 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylation phenotype and smoking
Number of subjects: 76
Study 9732842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acetylation phenotype or smoking)
Number of subjects: 76
Study 2699100 — intervention group
Group type: EXPERIMENTAL
Intervention: F XIII concentrate treatment
Number of subjects: 56
Study 2699100 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group
Number of subjects: 56
Study 30557370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 368
Study 28473136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 2604
Study 28473136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2604
Study 24081439 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fish oil (5.5 g/day)
Number of subjects: 60
Study 24081439 — intervention group
Group type: COMPARATOR
Intervention: Control (low dose fish oil 0.4 g/day)
Number of subjects: 60
Study 23318484 — intervention group
Group type: EXPERIMENTAL
Intervention: P/MC (sodium picosulfate and magnesium citrate)
Number of subjects: 603
Study 23318484 — intervention group
Group type: COMPARATOR
Intervention: 2L PEG‐3350 and bisacodyl tablets
Number of subjects: 603
Study 21247461 — intervention group
Group type: COMPARATOR
Intervention: Hospital management
Number of subjects: 240
Study 21247461 — intervention group
Group type: COMPARATOR
Intervention: Home management
Number of subjects: 240
Study 19531579 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 487
Study 19531579 — intervention group
Group type: COMPARATOR
Intervention: Bucindolol
Number of subjects: 487
Study 19531579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 16505266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 298
Study 16505266 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Acupuncture
Number of subjects: 298
Study 16505266 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 298
Study 16505266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture
Number of subjects: 298
Study 16505266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting List Control
Number of subjects: 298
Study 16505266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture at 26 weeks
Number of subjects: 298
Study 16505266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture at 52 weeks
Number of subjects: 298
Study 15482502 — intervention group
Group type: EXPERIMENTAL
Intervention: Social communication intervention with regular monthly therapist contact for 6 months and 2-monthly consolidation sessions for an additional 6 months.
Number of subjects: 28
Study 15482502 — intervention group
Group type: EXPERIMENTAL
Intervention: Social communication intervention
Number of subjects: 28
Study 15482502 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 28
Study 11058002 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 43
Study 11058002 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy alone (control)
Number of subjects: 43
Study 9274584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus Albendazole (200-400 micrograms/kg ivermectin and 400 mg albendazole)
Number of subjects: 113
Study 9274584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin alone (200-400 micrograms/kg, mean 273 micrograms/kg)
Number of subjects: 113
Study 9274584 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole alone (400 mg)
Number of subjects: 113
Study 9274584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 8384733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine
Number of subjects: 15
Study 8384733 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous vaccine
Number of subjects: 15
Study 8384733 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid fever patients
Number of subjects: 15
Study 3105886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate
Number of subjects: 10
Study 3105886 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (Control)
Number of subjects: 10
Study 31255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic unilateral laminotomy bilateral decompression
Number of subjects: 89
Study 31255456 — intervention group
Group type: COMPARATOR
Intervention: Microscopic unilateral laminotomy bilateral decompression
Number of subjects: 89
Study 31255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 89
Study 31255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic surgery
Number of subjects: 89
Study 28836120 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (MDI)
Number of subjects: 168
Study 28836120 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (BI)
Number of subjects: 168
Study 27373358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.3 mg/kg
Number of subjects: 100
Study 27373358 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) 2 ml
Number of subjects: 100
Study 25122671 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib (12 mg/kg/day)
Number of subjects: 44
Study 25122671 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day 4-weeks-on/2-weeks-off)
Number of subjects: 44
Study 25122671 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 44
Study 25122671 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 44
Study 22989021 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Activation Method (SAM)
Number of subjects: 102
Study 22989021 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 102
Study 20863554 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m² + Doxorubicin 45 mg/m² + G‐CSF 5 μg/kg (CD)
Number of subjects: 552